Management of intermittent atrial fibrillation: Drugs to maintain sinus rhythm

Journal of Cardiovascular Electrophysiology

Volumn 10, Issue 3, 1999, Pages 433-441

  Olgin, Jeffrey E ^a   Viskin, Sami ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DISOPYRAMIDE; FLECAINIDE; MEXILETINE; POTASSIUM; PROCAINAMIDE; PROPAFENONE; QUINIDINE; SODIUM CHANNEL; SOTALOL;

ANTIARRHYTHMIC ACTIVITY; ARRHYTHMOGENESIS; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; ELECTROCARDIOGRAM; HEADACHE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART REPOLARIZATION; HUMAN; META ANALYSIS; MORBIDITY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SINUS RHYTHM; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; VERTIGO; VISUAL DISORDER;

EID: 0032989371     PISSN: 10453873     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8167.1999.tb00697.x     Document Type: Conference Paper

References (63)

1. Takahashi N, Seki A, Imataka K, et al: Clinical features of paroxysmal atrial fibrillation: An observation of 94 patients. Jpn Heart J 1981;22:143-149.
2. Page PL, Hassanalizadeh H, Cardinal R: Transitions among atrial fibrillation, atrial flutter, and sinus rhythm during procainamide infusion and vagal stimulation in dogs with sterile pericarditis. Can J Physiol Pharmacol 1991;69:15-24.
3. Kopecky S, Gersh B, McGoon M, et al: The natural history of lone atrial fibrillation: A population based study over three decades. N Engl J Med 1987;317:669-674.
4. Tieleman RG, De Langen C, van Gelder IC, et al: Verapamil reduces tachycardia-induced electrical remodeling of the atria. Circulation 1997;95:1945-1953.
5. Tieleman RG, van Gelder IC, Crijns HJ, et al: Early recurrences of atrial fibrillation after electrical cardioversion: A result of fibrillation-induced electrical remodeling of the atria? J Am Coll Cardiol 1998;31:167-173.
6. Daoud EG, Knight BP, Weiss R, et al: Effect of verapamil and procainamide on atrial fibrillation-induced electrical remodeling in humans. Circulation 1997;96: 1542-1550.
7. Wijffels MC, Kirchhof CJ, Dorland R, et al: Atrial fibrillation begets atrial fibrillation: A study in awake chronically instrumented goats. Circulation 1995;92: 1954-1968.
8. van Gelder IC, Crijns HJ, Blanksma PK, et al: Time course of hemodynamic changes and improved of exercise tolerance after cardioversion of chronic atrial fibrillation unassociated with cardiac valve disease. Am J Cardiol 1993;72:560-566.
9. Flaker GC, Blackshear JL, McBride R, et al: Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol 1992;20:527-532.
10. Coplen SE, Antman EM, Berlin JA, et al: Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: A meta-analysis of randomized control trials. Circulation 1990;82:1106-1116.
11. Viskin S, Barron HV, Heller K, et al: The treatment of atrial fibrillation: Pharmacologic and nonpharmacologic strategies. Curr Probl Cardiol 1997;22:37-108.
12. Bianconi L, Boccadamo R, Pappalardo A, et al: Effectiveness of intravenous propafenone for conversion of atrial fibrillation and flutter of recent onset. Am J Cardiol 1989;64:335-338.
13. Gosselink AT, Crijns HJ, Van GI, et al: Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. JAMA 1992; 267:3289-3293.
14. Gold RL, Haffajee CI, Charos G, et al: Amiodarone for refractory atrial fibrillation. Am J Cardiol 1986;57:124-127.
15. Connolly SJ, Hoffert DL: Usefulness of propafenone for recurrent paroxysmal atrial fibrillation. Am J Cardiol 1989;63:817-819.
16. Pritchett EL, McCarthy EA, Wilkinson WE: Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias: A randomized, placebo-controlled, crossover trial in patients tolerating oral therapy. Ann Intern Med 1991;114:539-544.
17. Jackman WM, Friday KJ, Anderson JL, et al: The long QT syndrome: A critical review, new clinical observations, and a unifying hypothesis. Prog Cardiovasc Dis 1988;31:115-172.
18. Makkar RR, Fromm BS, Steinman RT, et al: Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993;270:2590-2597.
19. Nguyen PT, Scheinman MM, Seger J: Polymorphous ventricular tachycardia: Clinical characterization, therapy, and the QT interval. Circulation 1986;74:340-349.
20. Minardo JD, Heger JJ, Miles WM, et al: Clinical characteristics of patients with ventricular fibrillation during antiarrhythmic drug therapy. N Engl J Med 1988;319: 257-262.
21. Roden DM, Thompson KA, Hoffman BF, et al: Clinical features and basic mechanism of quinidine-induced arrhythmias. J Am Coll Cardiol 1986;8:73A-78A.
22. Prystowsky EN, Benson W, Fuster V, et al: Management of patients with fibrillation: A statement for healthcare professionals from the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. Circulation 1996;93:1262-1277.
23. Choy AM, Lang CC, Chomsky DM, et al: Normalization of acquired QT prolongation in humans by intravenous potassium. Circulation 1997;96:2149-2154.
24. Shimizu W, Antzelevitch C: Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing torsade de pointes in LQT2 and LQT3 models of the long-QT syndrome. Circulation 1997;96:2038-2047.
25. Kay GN, Plumb VJ, Arciniegas JG, et al: Torsade de pointes: The long-short initiating sequence and other clinical features: Observations in 32 patients. J Am Coll Cardiol 1983;2:806-817.
26. Locati EH, Schwartz PJ: The idiopathic long QT syndrome: Therapeutic management. PACE 1992;15: 1374-1379.
27. Viskin S, Alla SR, Barron HV, et al: Mode of onset of torsade de pointes in congenital long QT syndrome. J Am Coll Cardiol 1996;28:1262-1268.
28. Viskin S, Fish R, Roth A, et al: Prevention of torsade de pointes in the congenital long QT syndrome: Use of a pause prevention pacing algorithm. Heart 1998;79:417-419.
29. Lloyd EA, Gersh BJ, Forman R: The efficacy of quinidine and disopyramide in the maintenance of sinus rhythm after electroconversion from atrial fibrillation: A double-blind study comparing quinidine, disopyramide, and placebo. S Afr Med J 1984;65:367-369.
30. Karlson BW, Torstensson I, Abjom C, et al: Disopyramide in the maintenance of sinus rhythm after electroconversion of atrial fibrillation: A placebo-controlled one-year follow-up study. Eur Heart J 1988;9:284-290.
31. Coumel P, Attuel P, Leclercq JF, et al: Atrial arrhythmias of vagal or catecholaminergic origin: Comparative effects of beta-blocker treatment and the escape phenomenon. Arch Mal Coeur Vaiss 1982;75:373-387.
32. Coumel P, Friocourt P, Mugica J, et al: Long-term prevention of vagal atrial arrhythmias by atrial pacing at 90/minute: Experience with 6 cases. PACE 1983;6: 552-560.
33. Van Gelder IC, Crijns HJ, Van GW, et al: Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter. Am J Cardiol 1989;64:1317-1321.
34. Stroobandt R, Stiels B, Hoebrechts R: Propafenone for conversion and prophylaxis of atrial fibrillation. Propafenone Atrial Fibrillation Trial Investigators. Am J Cardiol 1997;79:418-423.
35. Anderson JL, Gilbert EM, Alpert BL, et al: Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy: A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide Supraventricular Tachycardia Study Group. Circulation 1989;80:1557-1570.
36. Lee SH, Chen SA, Chiang CE, et al: Comparisons of oral propafenone and quinidine as an initial treatment option in patients with symptomatic paroxysmal atrial fibrillation: A double-blind, randomized trial. J Intern Med 1996;239:253-260.
37. Lee SH, Chen SA, Tai CT, et al: Comparisons of oral propafenone and sotalol as an initial treatment in patients with symptomatic paroxysmal atrial fibrillation. Am J Cardiol 1997;79:905-908.
38. Naccarelli GV, Dorian P, Hohnloser SH, et al: Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. The Flecainide Multicenter Atrial Fibrillation Study Group. Am J Cardiol 1996;77:53A-59A.
39. Aliot E, Denjoy I: Comparison of the safety and efficacy of flecainide versus propafenone in hospital outpatients with symptomatic paroxysmal atrial fibrillation/flutter. The Flecainide AF French Study Group. Am J Cardiol 1996;77:66A-71A.
40. Chimienti M, Cullen MT Jr, Casadei G: Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias: Report from the Flecainide and Propafenone Italian Study (FAPIS) Group. Eur Heart J 1995;16:1943-1951.
41. Chimienti M, Cullen MT Jr, Casadei G: Safety of long-term flecainide and propafenone in the management of patients with symptomatic paroxysmal atrial fibrillation: Report from the Flecainide and Propafenone Italian Study Investigators. Am J Cardiol 1996;77:60A-75A.
42. Antman EM, Beamer AD, Cantillon C, et al: Therapy of refractory symptomatic atrial fibrillation and atrial flutter: A staged care approach with new antiarrhythmic drugs. J Am Coll Cardiol 1990;15:698-707.
43. Pritchett EL, DaTorre SD, Platt ML, et al: Flecainide acetate treatment of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation: Dose-response studies. The Flecainide Supraventricular Tachycardia Study Group. J Am Coll Cardiol 1991;17:297-303.
44. Mary RL, Kulbertus HE: Clinical efficacy of flecainide acetate in atrial fibrillation. Cardiology 1990;77:443-449.
45. Pritchett EL, Wilkinson WE: Mortality in patients treated with flecainide and encainide for supraventricular arrhythmias. Am J Cardiol 1991;67:976-980.
46. Anderson JL, Jolivette DM, Fredell PA: Summary of the efficacy and safety of flecainide for supraventricular arrhythmias. Am J Cardiol 1988;62:62D-66D.
47. Echt DS, Liebson PR, Mitchell LB, et al: Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781-788.
48. Falk RH: Flecainide-induced ventricular tachycardia and fibrillation in patients treated for atrial fibrillation. Ann Intern Med 1989;111:107-111.
49. Murdock CJ, Kyles AE, Yeung-Lai-Wah JA, et al: Atrial flutter in patients treated for atrial fibrillation with propafenone. Am J Cardiol 1990;66:755-757.
50. Kennedy HL, Brooks MM, Barker AH, et al: Beta-blocker therapy in the Cardiac Arrhythmia Suppression Trial. CAST Investigators. Am J Cardiol 1994;74:674-680.
51. Helmy I, Scheinman MM, Herre JM, et al: Electrophysiologic effects of isoproterenol in patients with atrioventricular reentrant tachycardia treated with flecainide. J Am Coll Cardiol 1990;16:1649-1655.
52. Auriechio A: Reversible protective effect of propafenone or flecainide during atrial fibrillation in patients with an accessory atrioventricular connection. Am Heart J 1992;124:932-937.
53. Myerburg RJ, Kessler KM, Cox MM, et al: Reversal of proarrhythmic effects of flecainide acetate and encainide hydrochloride by propranolol. Circulation 1989;80: 1571-1579.
54. Levy S, Lauribe P, Dolla E, et al: A randomized comparison of external and internal cardioversion of chronic atrial fibrillation. Circulation 1992;86:1415-1420.
55. Vitolo E, Tronci M, Larovere MT, et al: Amiodarone versus quinidine in the prophylaxis of atrial fibrillation. Acta Cardiol 1981;36:431-444.
56. Zehender M, Hohnloser S, Muller B, et al: Effects of amiodarone versus quinidine and verapamil in patients with chronic atrial fibrillation: Results of a comparative study and a 2-year follow-up. J Am Coll Cardiol 1992; 19:1054-1059.
57. Blevins RD, Kerin NZ, Benaderet D, et al: Amiodarone in the management of refractory atrial fibrillation. Arch Intern Med 1987;147:1401-1404.
58. Graboys TB, Podrid PJ, Lown B: Efficacy of amiodarone for refractory supraventricular tachyarrhythmias. Am Heart J 1983;106:870-876.
59. Koehiadakis GE, Igoumenidis NE, Marketou ME, et al: Low-dose amiodarone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol 1998;81:995-998.
60. Singh S, Saini RK, DiMarco J, et al: Efficacy and safety of sotalol in digitalized patients with chronic atrial fibrillation. The Sotalol Study Group. Am J Cardiol 1991;68:1227-1230.
61. Juul MS, Edvardsson N, Rehnqvist AN: Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation 1990;82:1932-1939.
62. Reimold SC, Cantillon CO, Friedman PL, et al: Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol 1993;71: 558-563.
63. Mason JW: A comparison of seven antiarrhythmic drugs in patients with ventricular arrhythmias. N Engl J Med 1993;329:452-458.